Raymond James Financial
CRSP icon

Raymond James Financial’s CRISPR Therapeutics CRSP Stock Holding History

Raymond James Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5M Buy
220,274
+53,126
+32% +$2.8M ﹤0.01% 1979
2025
Q4 		$8.77M Buy
167,148
+57,318
+52% +$3.43M ﹤0.01% 2084
2025
Q3 		$7.12M Buy
109,830
+12,257
+13% +$704K ﹤0.01% 2196
2025
Q2 		$4.75M Buy
97,573
+10,907
+13% +$422K ﹤0.01% 2410
2025
Q1 		$2.95M Buy
86,666
+4,571
+6% +$194K ﹤0.01% 2702
2024
Q4 		$3.23M Buy
+82,095
New +$3.88M ﹤0.01% 2615

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Raymond James Financial's CRSP Position: Q1 2026 in Review

Raymond James Financial increased its CRISPR Therapeutics (CRSP) stake by 32% in Q1 2026, buying an estimated $2.8M and bringing the position to 220,274 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1979.

Raymond James Financial first reported a position in CRSP in Q4 2024 and has held it in 6 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Raymond James Financial held 220,274 shares of CRISPR Therapeutics worth $10.5M as of Q1 2026.
  • Raymond James Financial bought 53,126 CRISPR Therapeutics shares in Q1 2026, an estimated $2.8M.
  • CRISPR Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #1979 holding.
  • Raymond James Financial first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.